annual cash & cash equivalents:
$1.04B-$1.81B(-63.44%)Summary
- As of today (June 22, 2025), PFE annual cash & cash equivalents is $1.04 billion, with the most recent change of -$1.81 billion (-63.44%) on December 31, 2024.
- During the last 3 years, PFE annual cash & cash equivalents has fallen by -$901.00 million (-46.35%).
- PFE annual cash & cash equivalents is now -89.65% below its all-time high of $10.08 billion, reached on December 31, 2012.
Performance
PFE Cash and cash equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly cash & cash equivalents:
$1.43B+$387.00M(+37.10%)Summary
- As of today (June 22, 2025), PFE quarterly cash & cash equivalents is $1.43 billion, with the most recent change of +$387.00 million (+37.10%) on March 29, 2025.
- Over the past year, PFE quarterly cash & cash equivalents has increased by +$711.00 million (+98.89%).
- PFE quarterly cash & cash equivalents is now -85.81% below its all-time high of $10.08 billion, reached on December 31, 2012.
Performance
PFE quarterly cash & cash equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Cash and cash equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
PFE Cash and cash equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -63.4% | +98.9% |
| 3 y3 years | -46.4% | -42.1% |
| 5 y5 years | -7.0% | -33.5% |
PFE Cash and cash equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -63.4% | +150.7% | -54.6% | +243.8% |
| 5 y | 5-year | -63.4% | +150.7% | -54.6% | +243.8% |
| alltime | all time | -89.7% | +161.7% | -85.8% | +648.7% |
PFE Cash and cash equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2025 | - | $1.43B(+37.1%) |
| Dec 2024 | $1.04B(-63.4%) | $1.04B(-4.5%) |
| Sep 2024 | - | $1.09B(+3.8%) |
| Jun 2024 | - | $1.05B(+46.3%) |
| Mar 2024 | - | $719.00M(-74.8%) |
| Dec 2023 | $2.85B(+585.8%) | $2.85B(-9.4%) |
| Sep 2023 | - | $3.15B(+19.6%) |
| Jun 2023 | - | $2.63B(+21.5%) |
| Mar 2023 | - | $2.17B(+420.7%) |
| Dec 2022 | $416.00M(-78.6%) | $416.00M(-68.0%) |
| Sep 2022 | - | $1.30B(-27.1%) |
| Jun 2022 | - | $1.78B(-27.9%) |
| Mar 2022 | - | $2.47B(+27.1%) |
| Dec 2021 | $1.94B(+8.8%) | $1.94B(-1.1%) |
| Sep 2021 | - | $1.97B(-17.1%) |
| Jun 2021 | - | $2.37B(+34.2%) |
| Mar 2021 | - | $1.77B(-1.0%) |
| Dec 2020 | $1.79B(+59.3%) | $1.79B(+12.5%) |
| Sep 2020 | - | $1.59B(-11.9%) |
| Jun 2020 | - | $1.80B(-16.3%) |
| Mar 2020 | - | $2.15B(+91.9%) |
| Dec 2019 | $1.12B(-1.6%) | $1.12B(-59.7%) |
| Sep 2019 | - | $2.79B(+56.1%) |
| Jun 2019 | - | $1.78B(-7.9%) |
| Mar 2019 | - | $1.94B(+70.1%) |
| Dec 2018 | $1.14B(-15.1%) | $1.14B(-68.0%) |
| Sep 2018 | - | $3.56B(+31.6%) |
| Jun 2018 | - | $2.70B(+17.5%) |
| Mar 2018 | - | $2.30B(+71.5%) |
| Dec 2017 | $1.34B(-48.3%) | $1.34B(-51.7%) |
| Sep 2017 | - | $2.78B(+7.5%) |
| Jun 2017 | - | $2.58B(-36.3%) |
| Mar 2017 | - | $4.06B(+56.3%) |
| Dec 2016 | $2.60B(-28.7%) | $2.60B(+23.9%) |
| Sep 2016 | - | $2.09B(-38.6%) |
| Jun 2016 | - | $3.41B(+33.2%) |
| Mar 2016 | - | $2.56B(-29.7%) |
| Dec 2015 | $3.64B(+8.9%) | $3.64B(+17.5%) |
| Sep 2015 | - | $3.10B(-15.6%) |
| Jun 2015 | - | $3.67B(+3.0%) |
| Mar 2015 | - | $3.56B(+6.6%) |
| Dec 2014 | $3.34B(+53.1%) | $3.34B(+37.2%) |
| Sep 2014 | - | $2.44B(-28.4%) |
| Jun 2014 | - | $3.41B(+19.0%) |
| Mar 2014 | - | $2.86B(+31.1%) |
| Dec 2013 | $2.18B(-78.3%) | $2.18B(+6.4%) |
| Sep 2013 | - | $2.05B(-15.8%) |
| Jun 2013 | - | $2.44B(+14.2%) |
| Mar 2013 | - | $2.13B(-78.8%) |
| Dec 2012 | $10.08B(+216.8%) | $10.08B(+123.7%) |
| Sep 2012 | - | $4.51B(+48.7%) |
| Jun 2012 | - | $3.03B(+3.3%) |
| Mar 2012 | - | $2.93B(-7.8%) |
| Dec 2011 | $3.18B(+83.4%) | $3.18B(-14.1%) |
| Sep 2011 | - | $3.71B(+19.7%) |
| Jun 2011 | - | $3.10B(+324.1%) |
| Mar 2011 | - | $730.00M(-57.9%) |
| Dec 2010 | $1.74B(-12.3%) | $1.74B(-20.3%) |
| Sep 2010 | - | $2.18B(+15.9%) |
| Jun 2010 | - | $1.88B(+6.7%) |
| Mar 2010 | - | $1.76B(-11.1%) |
| Dec 2009 | $1.98B(-6.8%) | $1.98B(-53.3%) |
| Sep 2009 | - | $4.23B(+88.7%) |
| Jun 2009 | - | $2.24B(+80.0%) |
| Mar 2009 | - | $1.25B(-41.2%) |
| Dec 2008 | $2.12B(-37.7%) | $2.12B(+67.7%) |
| Sep 2008 | - | $1.26B(+54.3%) |
| Jun 2008 | - | $820.00M(-59.3%) |
| Mar 2008 | - | $2.01B(-40.9%) |
| Dec 2007 | $3.41B(+86.4%) | $3.41B(+30.4%) |
| Sep 2007 | - | $2.61B(+22.1%) |
| Jun 2007 | - | $2.14B(-14.2%) |
| Mar 2007 | - | $2.49B(+36.4%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2006 | $1.83B(-18.7%) | $1.83B(+55.2%) |
| Sep 2006 | - | $1.18B(-38.7%) |
| Jun 2006 | - | $1.92B(-33.0%) |
| Mar 2006 | - | $2.87B(+27.7%) |
| Dec 2005 | $2.25B(+24.3%) | $2.25B(+134.3%) |
| Sep 2005 | - | $959.00M(-24.8%) |
| Jun 2005 | - | $1.28B(-13.6%) |
| Mar 2005 | - | $1.48B(-18.4%) |
| Dec 2004 | $1.81B(+18.9%) | $1.81B(-3.0%) |
| Sep 2004 | - | $1.86B(+185.9%) |
| Jun 2004 | - | $652.00M(-32.4%) |
| Mar 2004 | - | $965.00M(-36.5%) |
| Dec 2003 | $1.52B(-19.1%) | $1.52B(-5.6%) |
| Sep 2003 | - | $1.61B(-26.5%) |
| Jun 2003 | - | $2.19B(+5.9%) |
| Mar 2003 | - | $2.07B(+10.1%) |
| Dec 2002 | $1.88B(+81.3%) | $1.88B(+5.9%) |
| Sep 2002 | - | $1.77B(+48.3%) |
| Jun 2002 | - | $1.20B(-10.2%) |
| Mar 2002 | - | $1.33B(+28.6%) |
| Dec 2001 | $1.04B(-5.7%) | $1.04B(-45.4%) |
| Sep 2001 | - | $1.90B(+46.6%) |
| Jun 2001 | - | $1.29B(+10.1%) |
| Mar 2001 | - | $1.18B(+7.0%) |
| Dec 2000 | $1.10B(-53.4%) | $1.10B(-18.0%) |
| Sep 2000 | - | $1.34B(-15.7%) |
| Jun 2000 | - | $1.59B(+732.5%) |
| Mar 2000 | - | $191.00M(-91.9%) |
| Dec 1999 | $2.36B(+51.9%) | $2.36B(+150.3%) |
| Sep 1999 | - | $942.00M(-23.0%) |
| Jun 1999 | - | $1.22B(+4.9%) |
| Mar 1999 | - | $1.17B(-24.9%) |
| Dec 1998 | $1.55B(+77.0%) | $1.55B(-43.0%) |
| Sep 1998 | - | $2.72B(+150.0%) |
| Jun 1998 | - | $1.09B(+3.4%) |
| Mar 1998 | - | $1.05B(+20.1%) |
| Dec 1997 | $877.00M(-23.7%) | $877.00M(-26.3%) |
| Sep 1997 | - | $1.19B(-21.4%) |
| Jun 1997 | - | $1.51B(+23.1%) |
| Mar 1997 | - | $1.23B(+7.0%) |
| Dec 1996 | $1.15B(+185.1%) | $1.15B(+9.9%) |
| Sep 1996 | - | $1.05B(+20.2%) |
| Jun 1996 | - | $870.00M(+6.4%) |
| Mar 1996 | - | $818.00M(+102.8%) |
| Dec 1995 | $403.30M(-72.3%) | $403.30M(-45.0%) |
| Sep 1995 | - | $733.60M(+17.6%) |
| Jun 1995 | - | $623.60M(-35.5%) |
| Mar 1995 | - | $967.00M(-33.7%) |
| Dec 1994 | $1.46B(+100.0%) | $1.46B(+63.1%) |
| Sep 1994 | - | $894.20M(+11.2%) |
| Jun 1994 | - | $804.10M(+0.9%) |
| Mar 1994 | - | $796.80M(+9.2%) |
| Dec 1993 | $729.40M(-42.0%) | $729.40M(-40.6%) |
| Sep 1993 | - | $1.23B(+5.9%) |
| Jun 1993 | - | $1.16B(+13.8%) |
| Mar 1993 | - | $1.02B(-18.9%) |
| Dec 1992 | $1.26B(-4.6%) | $1.26B(+16.4%) |
| Sep 1992 | - | $1.08B(+14.6%) |
| Jun 1992 | - | $941.90M(-11.6%) |
| Mar 1992 | - | $1.07B(-19.1%) |
| Dec 1991 | $1.32B(+51.4%) | $1.32B(+95.6%) |
| Sep 1991 | - | $673.50M(-0.3%) |
| Jun 1991 | - | $675.80M(+11.0%) |
| Mar 1991 | - | $608.90M(-30.0%) |
| Dec 1990 | $870.30M(+5.4%) | $870.30M(+182.7%) |
| Sep 1990 | - | $307.90M(-22.9%) |
| Jun 1990 | - | $399.10M(+2.6%) |
| Mar 1990 | - | $388.90M(-52.9%) |
| Dec 1989 | $825.40M(+2.2%) | $825.40M(+2.2%) |
| Dec 1988 | $807.50M(-21.7%) | $807.50M(-21.7%) |
| Dec 1987 | $1.03B(+158.7%) | $1.03B(+158.7%) |
| Dec 1986 | $398.60M(-3.4%) | $398.60M(-3.4%) |
| Dec 1985 | $412.60M(-53.2%) | $412.60M(-53.2%) |
| Dec 1984 | $880.90M | $880.90M |
FAQ
- What is Pfizer annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Pfizer?
- What is Pfizer annual cash & cash equivalents year-on-year change?
- What is Pfizer quarterly cash & cash equivalents?
- What is the all time high quarterly cash & cash equivalents for Pfizer?
- What is Pfizer quarterly cash & cash equivalents year-on-year change?
What is Pfizer annual cash & cash equivalents?
The current annual cash & cash equivalents of PFE is $1.04B
What is the all time high annual cash & cash equivalents for Pfizer?
Pfizer all-time high annual cash & cash equivalents is $10.08B
What is Pfizer annual cash & cash equivalents year-on-year change?
Over the past year, PFE annual cash & cash equivalents has changed by -$1.81B (-63.44%)
What is Pfizer quarterly cash & cash equivalents?
The current quarterly cash & cash equivalents of PFE is $1.43B
What is the all time high quarterly cash & cash equivalents for Pfizer?
Pfizer all-time high quarterly cash & cash equivalents is $10.08B
What is Pfizer quarterly cash & cash equivalents year-on-year change?
Over the past year, PFE quarterly cash & cash equivalents has changed by +$711.00M (+98.89%)